Tefibazumab

Drug Profile

Tefibazumab

Alternative Names: S. aureus monoclonal antibody - Inhibitex; Staphylococcus aureus monoclonal antibody - Inhibitex; Aurexis; Humanised mAb 12-9 - Inhibitex; INH-H2002

Latest Information Update: 17 Feb 2012

Price : $50

At a glance

  • Originator Inhibitex
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Staphylococcal infections

Most Recent Events

  • 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
  • 22 Nov 2010 Tefibazumab is available for licensing as of 22 Nov 2010. http://www.inhibitex.com
  • 21 Aug 2007 Tefibazumab is available for licensing (http://www.inhibitex.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top